Global /Bangladesh /Healthcare /Drug Manufacturers - General /IBNSINA
chevron_leftBack
The IBN SINA Pharmaceutical Industry PLC logo

The IBN SINA Pharmaceutical Industry PLC

IBNSINA
DSE: IBNSINA Delayed
312.40BDT 0.1%
2.55 USD
As of 6 June 2026, The IBN SINA Pharmaceutical Industry PLC has a market cap of $79.58M USD, ranking #27189 globally and #67 in Bangladesh. It ranks #2446 in the Healthcare sector, and #881 in the Drug Manufacturers - General industry.
Global Rank
27189
Country Rank
67
Sector Rank
2446
Industry Rank
881
Key Stats
Market Cap
$79.58MUSD
9.76B BDT
Enterprise Value
$106.38MUSD
13.05B BDT
Revenue (TTM)
$109.86MUSD
13.48B BDT
EBITDA (TTM)
$10.39MUSD
1.27B BDT
Net Income (TTM)
$6.43MUSD
788.34M BDT
EBITDA Margin
9.5%
Profit Margin
5.9%
PE Ratio
12.4
PS Ratio
0.7
PB Ratio
2.2
EV/EBITDA
10.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
A. K. Sadrul Islam open_in_new
Employees
5,200
Founded
1983
Website
ibnsinapharma.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.1% -2% -2.3% -5.6% 6.8% 6.7%

News

Loading...

Markets

Exchange Ticker Price
Dhaka Stock Exchange
MIC: XDHA
PRIMARY
IBNSINA
ISIN: BD0464IBNSN2
Shares Out.:
31.244M1 Shares Float: 17.297M2
TV:
SA:
YF:
GF:
BA:
MS:
312.40 BDT
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About The IBN SINA Pharmaceutical Industry PLC

The IBN SINA Pharmaceutical Industry PLC produces and sells pharmaceutical drugs in Bangladesh and internationally. The company provides its products in various forms, such as solid dosage forms consisting of tablets and capsules; parenteral products covering ampoules and vials; liquid dosage forms comprising syrups, solutions, suspensions, and powder for suspension (dry syrups); and sterile ophthalmic products, creams, ointments, gels, eye drops and sachet, etc. It also offers various therapeutic products, including analgesic and anti-inflammatory, anti-dementia, anti-heamorrhoidal, anti-allergic-occular, anti-arthritis supplement, anti-asthmatic, anti-emetic, anti-fibrinolytic, anti-fungal, anti-glucoma, anti-histamine, anti-malarial, anti-melasma, anti-neuropathic, anti-protozoal, anti-spasmodic, anti-ulcerant, antibacterial, antibiotic, anticataract, anti-diabetic, anti-helmintic, antimigraine agent, antivertigo agent, and antiviral products. In addition, the company’s therapeutic products comprise antibiotic and steroid, gastrointestinal and skin diseas, antibiotic-occular, antifungal-occular, antiviral-occular, anxiolytic and antidepressant, aromatase inhibitor, bile acid, bisphosphonates, calcium supplement, cardiovascular preparation, corticosteroid, cough expectorant, dry eye syndrome, gastroprokinetic agent, haematinic/vitamin and mineral, hand rub, hormone products, intestinal anti-inflammatory, laxative, multivitamin and multi-minerals, muscle relaxant, mydriatic agents, nootropic, ORS, topical, urological preparation products. Further, it provides herbal and Unani products; and manufactures and trades in active pharmaceutical ingredients, natural medicines, polymer plastic bottles, plastic tubes, laminated tubes, and other related products. The company was incorporated in 1983 and is headquartered in Dhaka, Bangladesh.

Similar Companies

Industry: Drug Manufacturers - General (Bangladesh)
Name
Market Cap diff.
PE
SQURPHARMA
$1.54B
189.43B BDT
2K%
7.3
$417.54M
51.21B BDT
425%
8.1
RENATA
$389.85M
47.82B BDT
390%
18.9
UNILEVERCL
$326.4M
40.03B BDT
310%
55.4
BEACONPHAR
$194.17M
23.82B BDT
144%
19.2
$145.51M
17.85B BDT
83%
154.3
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
957K%
38.1
JNJ
$547.28B
688K%
26.4
ABBV
$360.63B
453K%
97.4
$324.68B
256.25B CHF
408K%
19.9
AZN
$289.43B
215.59B GBP
364K%
27.6
NOVN
$277.35B
218.9B CHF
348K%
20.5
chevron_leftBack